A Single Center, Open-label, Single Sequence Study to Evaluate the Potential Drug Interaction of CYP3A4 Inducer Rifampicin With SY-004 Capsules in Healthy Subjects
Latest Information Update: 21 May 2022
At a glance
- Drugs Globalagliatin (Primary) ; Rifampicin
- Indications Type 2 diabetes mellitus
- Focus Pharmacokinetics
- Sponsors Suzhou Yabao Pharmaceutical
- 17 May 2022 Status changed from not yet recruiting to completed.
- 01 Jun 2021 New trial record